Outsource with confidence
Partner with us and you will experience a transparent and consultative partnership. Our ethos of flexibility and open communication provides our customers with the resourceful, adaptable strategies they need to ensure projects are completed successfully, on budget and on time.
We ensure that our scientists stay informed of state-of-the-art practices in the industry, which allows us to maintain vital knowledge in the virotherapy sector. This expertise allows us to not only understand but also overcome your technical challenges.
Following a 15-year track record in virotherapy and vaccine manufacturing, in May 2019, Vibalogics was acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.
The investment has played an important part in our growth strategy both in Europe and the United States, as we look to expand our capabilities to manufacture late-stage and commercial products in the near future.
Why not join us in Germany to inspect our facility, meet our passionate team of subject matter experts and discuss your project?
Expect open and honest collaboration. Expect exceptional quality. Experience a unique understanding of virotherapy.
Get in touch today